In this study, effects of γδT cells on human Breast Cancer in combination with tumor reducing
      surgery, for example, cryosurgery going to be investigated.

Safety and Efficiency of γδ T Cell Against Breast Cancer

Breast Cancer

Breast tumor will be removed using tumor reducing surgery such as cryosurgery. PBMC of the
      patient will be separated from peripheral blood. After making them potential cancer killer γδ
      T Cell, they will be infused to the patients as an immunotherapy treatment NOTE: Originally,
      our designed proposal was to use autologous PBMCs from cancer patients to ex vivo expand
      Vγ9Vδ2-T cells, and then perform adoptive transfer therapy. However, PBMCs of majority of
      cancer patients could not be effectively expanded, including cell number, cell purity and
      cell function could not meet the requirements of reinfusion. Meanwhile, those patients could
      not tolerate 100ml of blood drawing for culture every 2 ~ 3 weeks.

      Therefore, we submitted new clinical study application to the ethical committee of the Fuda
      Hospital affiliated with Jinan University (Guangzhou, PR. China) by changing the autologous
      protocol with the allogeneic protocol. After the allogeneic protocol was approved, we adapted
      allogeneic cells instead of autologous in our subsequentially clinical study.

Cryosurgery , IRE surgery ,surgery

γδ T cells

γδ T cells/ Surgery

γδ T Cell Immunotherapy for Treatment of Breast Cancer

In this group, the patients will receive under CT Cryosurgery , IRE surgery or open surgery to control the local tumor

In this group, the patients will receive multiple high-activity γδ T cell immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)

In this group, the patients will receive multiple high-activity γδ T cell immunotherapies and Cryosurgery, IRE surgery or open surgery

Safety and Efficiency of γδ T Cell Against Breast Cancer

About this trial

Study ID

Status

Type

Phase

Placebo

Accepting

Not accepting

Trial Timing

What is this trial about?

What are the participation requirements?